ストックスクリーナーアプリを入手
31.85
0.19%
0.06
プレマーケット:
31.85
前日終値:
$31.79
開ける：
$31.91
24時間の取引高:
436.08K
Relative Volume:
0.75
時価総額：
$1.52B
収益：
-
当期純損益:
$-86.97M
株価収益率:
-13.17
EPS:
-2.4189
ネットキャッシュフロー:
$-81.88M
1週間 パフォーマンス:
-1.85%
1か月 パフォーマンス:
-5.15%
6か月 パフォーマンス:
+17.61%
1年 パフォーマンス:
+154.60%
1日の値動き範囲:
$31.21
$32.89
1週間の範囲:
$29.60
$33.11
52週間の値動き範囲:
$9.43
$45.85
Mbx Biosciences Inc Stock (MBX) Company Profile
Compare MBX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
31.85 | 1.51B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-12-04 | 開始されました | Goldman | Sell |
| 2025-11-04 | 開始されました | TD Cowen | Buy |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-08-15 | 再開されました | Jefferies | Buy |
| 2025-08-05 | 開始されました | Mizuho | Outperform |
| 2025-07-16 | 開始されました | Oppenheimer | Outperform |
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
すべてを表示
Mbx Biosciences Inc (MBX) 最新ニュース
MBX Technical Analysis | Trend, Signals & Chart Patterns | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
MBX Biosciences, Inc. thanks clinical trial participants as new therapies progress - Traders Union
MBX Biosciences (MBX) price target increased by 11.23% to 69.55 - MSN
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $91 - Moomoo
Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance
MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge - Sahm
Insider sale notice: 15,000 shares planned | MBX SEC FilingForm 144 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
MBX Biosciences (NASDAQ:MBX) Trading Down 8.8%Here's What Happened - MarketBeat
A Quick Look at Today's Ratings for MBX Biosciences(MBX.US), With a Forecast Between $56 to $86 - Moomoo
AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements - Benzinga
MBX Biosciences (NASDAQ:MBX) Price Target Raised to $86.00 at Citizens Jmp - MarketBeat
Q2 EPS Estimates for MBX Biosciences Boosted by Analyst - MarketBeat
Citizens raises MBX Biosciences stock price target on obesity drug data By Investing.com - Investing.com South Africa
Citizens raises MBX Biosciences stock price target on obesity drug data - Investing.com Nigeria
MBX Biosciences stock hits all-time high at 44.98 USD By Investing.com - Investing.com India
MBX Biosciences reports early obesity drug trial data By Investing.com - Investing.com Australia
Stifel raises MBX Biosciences stock price target to $56 on obesity data - Investing.com UK
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics PortfolioSlideshow (NASDAQ:MBX) 2026-05-11 - Seeking Alpha
Stifel raises MBX Biosciences stock price target to $56 on obesity data By Investing.com - Investing.com South Africa
MBX highlights early data for monthly obesity drug MBX-4291 - BioWorld News
Mbx Biosciences Insider Sold Shares Worth $2,685,515, According to a Recent SEC Filing - marketscreener.com
MBX Biosciences (MBX) CMO exercises options and sells 70,003 shares under 10b5-1 plan - Stock Titan
MBX (NASDAQ) affiliate sells multiple tranches of shares in Rule 144 notices - Stock Titan
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push - MarketBeat
MBX: MBX 4291 achieves 7% mean weight loss with strong tolerability in phase I, supporting monthly dosing - TradingView
Insiders Of MBX Biosciences Are Up 125% On Their US$1.06m Purchase - Moomoo
MBX Biosciences (NASDAQ:MBX) Price Target Raised to $70.00 - MarketBeat
MBX Biosciences Reports Positive Phase 1 Results for Once-Monthly Obesity Drug MBX 4291 and Expands Obesity Pipeline - Minichart
MBX: MBX's obesity pipeline advances with promising once-monthly candidates and strong financial runway - TradingView
MBX Biosciences : May 2026 Obesity Day Presentation – Final - marketscreener.com
MBX Biosciences stock hits all-time high at 44.98 USD - Investing.com
Obesity portfolio update features new clinical data from MBX Biosciences, Inc. - Traders Union
MBX Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Truist Raises Price Target on MBX Biosciences to $70 From $50, Keeps Buy Rating - marketscreener.com
MBX Biosciences Highlights Positive Phase 1 Obesity Data - TipRanks
MBX Biosciences reports early obesity drug trial data - Investing.com
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing - The Manila Times
MBX Biosciences, Inc. Provides Obesity Portfolio Update Including Initial Phase 1 Data For MBX 4291 Supporting Potential For Once-Monthly Dosing - marketscreener.com
Brokers Set Expectations for MBX Biosciences Q1 Earnings - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Its Recent Share Price Momentum - Sahm
Wall Street Zen Upgrades MBX Biosciences (NASDAQ:MBX) to Hold - MarketBeat
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Top MBX Biosciences Executive Makes Notable Stock Move - TipRanks
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):